Medicare Enrolled

Dr. Rodney Daniel, MD MSCR

Rheumatology · Oldsmar, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Speaking/Promotional
106 STATE ST E, Oldsmar, FL 34677
7272630800
In practice since 2006 (19 years)
NPI: 1912094822 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Daniel from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Daniel? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Daniel

Dr. Rodney Daniel is a rheumatology in Oldsmar, FL, with 19 years in practice. Based on federal Medicare data, Dr. Daniel performed 198,872 Medicare services across 1,227 unique beneficiaries.

Between the years covered by Open Payments, Dr. Daniel received a total of $362,511 from 56 pharmaceutical and/or device companies across 2300 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Daniel is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice▲ Top 9% volume in FL$ $362,511 industry payments

Medicare Practice Summary

Medicare Utilization ↗
198,872
Medicare services
Top 9% in FL for rheumatology
1,227
Unique beneficiaries
$8
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~10,467 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Tocilizumab injection (Actemra)91,600$5$11
Certolizumab injection (Cimzia)43,010$4$11
Romosozumab injection (Evenity) for osteoporosis23,100$8$23
Golimumab infusion (Simponi Aria)17,640$10$26
Abatacept infusion (Orencia)10,650$34$82
Denosumab injection (Prolia/Xgeva)9,840$18$44
Administration of chemotherapy into vein, 1 hour or less594$96$345
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle527$52$189
Blood draw (venipuncture)433$8$20
Office visit, established patient (30-39 min)431$88$270
Administration of chemotherapy into vein, each additional hour340$22$110
Office visit, established patient, complex (40-54 min)259$136$364
Betamethasone steroid injection114$5$12
Injection of additional new drug or substance into vein95$12$85
Joint injection, major joint71$57$234
New patient office visit, complex (60-74 min)62$162$521
Steroid injection (triamcinolone)57$0$15
Office visit, established patient (20-29 min)30$70$184
New patient office visit (45-59 min)19$119$432
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
14.2% high complexity
85.2% medium
0.6% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$362,511
Total received (2018-2024)
Avg $51,787/year across 7 years
Top 4% in FL for rheumatology
56
Companies
2,300
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$252,968 (69.8%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$81,586 (22.5%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$27,957 (7.7%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$78,900
2023
$101,428
2022
$70,719
2021
$24,015
2020
$28,991
2019
$31,884
2018
$26,575

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
GENZYME CORPORATION
$107,762
Boehringer Ingelheim Pharmaceuticals, Inc.
$76,325
AbbVie Inc.
$43,123
AbbVie, Inc.
$36,603
ABBVIE INC.
$33,014
PFIZER INC.
$11,805
Alexion Pharmaceuticals, Inc.
$10,579
Fresenius Kabi USA, LLC
$9,062
Amgen Inc.
$5,485
Gilead Sciences, Inc.
$5,284
Novartis Pharmaceuticals Corporation
$4,227
UCB, Inc.
$3,292
Janssen Biotech, Inc.
$3,030
GlaxoSmithKline, LLC.
$1,353
E.R. Squibb & Sons, L.L.C.
$1,253
Mallinckrodt Hospital Products Inc.
$1,244
Lilly USA, LLC
$1,150
Horizon Therapeutics plc
$983
Genentech USA, Inc.
$943
AstraZeneca Pharmaceuticals LP
$726
Radius Health, Inc.
$675
ANI Pharmaceuticals, Inc.
$474
Aurinia Pharma U.S., Inc.
$399
Zyla Life Sciences
$374
Merck Sharp & Dohme Corporation
$339
Antares Pharma, Inc.
$324
Organon LLC
$288
SANOFI-AVENTIS U.S. LLC
$278
Egalet US Inc
$244
Horizon Pharma plc
$194
Mallinckrodt LLC
$156
MEDEXUS PHARMA, INC.
$134
Takeda Pharmaceuticals U.S.A., Inc.
$133
Mallinckrodt Enterprises LLC
$130
Sobi, Inc
$127
Johnson & Johnson Health Care Systems Inc.
$126
Sandoz Inc.
$120
Flexion Therapeutics, Inc.
$113
Zyla Life Sciences, Inc.
$104
Exeltis, USA Inc.
$85
IDORSIA PHARMACEUTICALS US INC
$82
Celgene Corporation
$65
Kyowa Kirin, Inc.
$46
Kiniksa Pharmaceuticals, Ltd.
$36
United Therapeutics Corporation
$25
Organon Llc
$23
SOBI, INC
$22
Genentech, Inc.
$21
Hikma Pharmaceuticals USA
$18
Bioventus LLC
$18
NeuroMetrix Inc
$18
Fidia Pharma USA Inc.
$16
Assertio Therapeutics, Inc.
$16
Kiniksa Pharmaceuticals International, plc
$14
ADMA BioManufacturing LLC
$14
Amarin Pharma Inc.
$13
Top 3 companies account for 62.7% of total payments
Associated products mentioned in payments ›
ACTHAR · AMJEVITA · AVSOLA · Actemra · Arcalyst · BENLYSTA · Bimzelx · COSENTYX · CYLTEZO · Cimzia · Crysvita · DUEXIS · Durolane · ENTYVIO · EVENITY · EVUSHELD · Enbrel · FASENRA · FORTEO · GRALISE · HADLIMA · HUMIRA · HYMOVIS · HYRIMOZ · Humira · IDACIO · ILARIS · INFLECTRA · KEVZARA · KINERET · KISUNLA · KRYSTEXXA · Kineret · LUPKYNIS · LYRICA · Mitigare · NO PRODUCT DISCUSSED · NUCALA · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OFEV · OLUMIANT · OMVOH · ORENCIA · OTREXUP · OXAYDO · Otezla · Otrexup · PENNSAID · PREVNAR - 13 · PURIFIED CORTROPHIN GEL · Prolia · QUVIVIQ · RAYOS · REMICADE · RENFLEXIS · RINVOQ · Rasuvo · Rinvoq · Rituxan · SAPHNELO · SIMPONI · SIMPONI ARIA · SKYRIZI · SOLIQUA · SPRIX · STELARA · STRENSIQ · TALTZ · TAVNEOS · TEPEZZA · TREMFYA · TYVASO · Tavneos · Tyenne · Tymlos · Uloric · VIMOVO · Vascepa · XELJANZ · XYOSTED · ZORVOLEX · Zilretta
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (70%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in rheumatology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 4% for rheumatology in FL.

Equivalent to $182 per 100 Medicare services performed
Looking for a rheumatology in Oldsmar?
Compare rheumatologys in the Oldsmar area by procedure volume, costs, and industry payment transparency.
Browse rheumatologys nearby

Geographic Context

Rheumatologys within 10 mi
54
Per 100K population
5.6
County median income
$70,293
Nearest hospital
MEASE COUNTRYSIDE HOSPITAL
2.7 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Daniel is a mixed practice specialist, with above-average Medicare volume (top 9% in FL), and high industry engagement (speaking/promotional, top 4%), with 19 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Daniel experienced with tocilizumab injection (actemra)?
Based on Medicare claims data, Dr. Daniel performed 91,600 tocilizumab injection (actemra) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Daniel receive payments from pharmaceutical companies?
Yes. Dr. Daniel received a total of $362,511 from 56 companies across 2,300 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Daniel's costs compare to other rheumatologys in Oldsmar?
Dr. Daniel's average Medicare payment per service is $8. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Daniel) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →